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Patients with aﬁbrinogenemia or hypoﬁbrinogenemia present a unique challenge to the arthroplasty
surgeon as ﬁbrinogen is a key contributor to hemostasis. Patients with these disorders are known to have
a higher risk for postsurgical bleeding complications. We present the case of a patient with hypoﬁ-
brinogenemia who underwent an elective total knee arthroplasty. Our colleagues in hematology-
oncology guided us initially to achieve and maintain appropriate ﬁbrinogen levels in the early
perioperative period. However, the patient developed an acute joint effusion and subsequent infection 4
weeks after her initial operation. Her ﬁbrinogen levels were noted to have fallen below the target range
by that time, and it was also revealed that the patient failed to follow-up with hematology-oncology to
monitor her levels. Based on our review of the available literature, we recommend that patient's
ﬁbrinogen levels be closely monitored and maintained ideally >100 mg/dL not only in the initial peri-
operative window but perhaps for the ﬁrst 4-6 weeks postoperatively as well.
© 2015 The Authors. Published by Elsevier Inc. on behalf of The American Association of Hip and Knee
Surgeons. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Aﬁbrinogenemia and hypoﬁbrinogenemia, deﬁned as plasma
ﬁbrinogen levels <150 mg/dL, are rare coagulation disorders with
an incidence of 1 in 1 million [1,2]. Of all coagulation disorders,
ﬁbrinogen deﬁciency has been reported approximately 8% of the
time [3].
Fibrinogen serves as a key contributor to hemostasis by
assisting in clot formation, platelet aggregation, and ﬁbrinolysis
[4,5]. Treatment for congenital ﬁbrinogen deﬁciency can consist
of replacement with fresh frozen plasma (FFP), cryoprecipitate
(cryo), or ﬁbrinogen concentrate (FC). Clinically, symptoms mayclosed potential or pertinent
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c-nd/4.0/).vary depending on the severity of the deﬁciency. Patients
with hypoﬁbrinogenemia are typically asymptomatic; however,
they may be at risk for bleeding complications when
exposed to trauma, pregnancy, or surgery. Those with aﬁ-
brinogenemia tend to have a higher frequency of bleeding in
comparison [3,4].
Unfortunately, there is limited literature and a lack of guidelines
regarding the optimal perioperative management of these patients.
The few reported cases consist of those with severe or complete
deﬁciency of ﬁbrinogen in the setting of trauma and pregnancy
where signiﬁcant bleeding is often expected [6]. In all cases, current
recommendations suggest maintaining ﬁbrinogen level above 100-
200 mg/dL to prevent bleeding complications [2,7,8]. Currently, no
clinical cases, guidelines, or recommendations exist for patients
with congenital ﬁbrinogen deﬁciency undergoing total joint
arthroplasty.
We report the case of a patient with congenital hypoﬁ-
brinogenemia who underwent an elective total knee arthroplasty
(TKA) and unfortunately suffered a postoperative hemarthrosis and
acute prosthetic joint infection. We discuss our experience with the
perioperative management of this challenging patient.ciation of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-
Figure 1. Preoperative radiograph of the patient showing osteoarthritic changes which unfortunately not managed sufﬁciently with nonoperative measures.
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A 67-year-old female had a medical history signiﬁcant for
hypoﬁbrinogenemia and right knee pain related to moderate tri-
compartmental osteoarthritis. Of note, written informed consent
was obtained from the patient for publication of this case report
and accompanying images. She presented to our institution after a
fall resulting in a closed right patella fracture with an intact
extensor mechanism, which was treated conservatively. She
continued to complain of right knee pain despite radiographic ev-
idence of complete fracture healing. Physical examination and
subsequent radiographs suggested that her ongoing discomfort
was more likely secondary to worsening tricompartmental
arthritis, particularly involving the patellofemoral joint (Fig. 1).
Given her active functional status, it was determined that she
would beneﬁt from a total knee arthroplasty.Figure 2. Postoperative radiographs after the indHer family history was signiﬁcant for a grandmother who died
because of hemorrhagic shock while delivering her father, as well
as a daughter with known hypoﬁbrinogenemia. The patient's sur-
gical history is signiﬁcant for a wisdom tooth extraction, vaginal
delivery, gastric band placement, and colectomy for diverticulitis
without any signiﬁcant bleeding episodes. She was diagnosed with
hypoﬁbrinogenemia based on abnormal coagulation proﬁle labo-
ratory values obtained due to the positive family history that had
prompted an in-depth hematology workup.
Before her elective right TKA, her preadmission laboratories
demonstrated a ﬁbrinogen level of 58 mg/dL (normal range: 150-
480 mg/dL), international normalized ratio (INR) of 1.3 (normal
range: 0.8-1.2), prothrombin time (PT) of 13.2 seconds (normal
range: 9.5-12.5 seconds), and activated partial thromboplastin time
(aPTT) of 31 seconds (normal range: 24-37 seconds). Hematology
was consulted for perioperative management and recommendedex operation for the total knee replacement.
Figure 3. Radiographs of the patient showing stable alignment at her most recent clinic visit after the operation for the joint infection.
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hospital's infusion center. Accordingly, the patient received 875 mg
of ﬁbrinogen (~10 mg/kg) raising her preoperative ﬁbrinogen level
to 116 mg/dL, immediately before the TKA, which was then per-
formed on the same morning after the infusion.
At the time of surgery, a standard medial parapatellar approach
was used. The synovium and articular cartilage were noted to be
grossly stained with brown hemosiderin deposition. The case was
uneventful without any intraoperative complications or excessive
bleeding. Hemostasis was actively achieved throughout the oper-
ation; the tourniquet was inﬂated only for ﬁnal bony preparationFigure 4. The structure of ﬁbrinogen showing the two identical polypeptide chains that co
(Adapted: The Plasma Proteins, 2nd ed., 2, Putnam, F.W., ed, p. 148).and cementation for 30 minutes, and the estimated blood loss was
100 mL.
The surgical incision was closed in a standard multilayered
fashion with absorbable sutures, followed by the injection of 1000
mg of intra-articular tranexamic acid for topical hemostasis, which
is the current standard of care at our institution [9]. She received
our institution's routine perioperative prophylactic antibiotic
regimen of 2-g cefazolin and also had 1.2 g of tobramycin mixed
with the bone cement for the implant. A compressive dressing was
applied along with a knee immobilizer after the procedure. These
were used to rest the knee joint and minimize tissue shear,nstitute the protein.
Figure 5. Simple coagulation cascade showing the role of ﬁbrinogen (http://imgbuddy.
com/simple-coagulation-cascade.asp).
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reduce the risk of postoperative hemarthrosis. She was allowed to
bear weight as tolerated during that time with the knee straight.
Postoperative radiographs showed acceptable positioning and
alignment of the implants (Fig. 2).
Postoperatively, the patient's ﬁbrinogen levels were checked
daily and maintained above 100 mg/dL throughout her 3-day
inpatient stay. As per our protocol, she received oral 325-mg
enteric-coated aspirin twice daily for deep vein thrombosis pro-
phylaxis for 30 days. Her immediate postoperative course was
otherwise unremarkable without any signs or symptoms of
excessive bleeding. She was discharged safely to home on post-
operative day 3.
Twenty-ﬁve days after her index procedure, the patient pre-
sented to the emergency department with an acute onset of right
knee swelling and worsening pain. The patient noted a recent in-
crease in her level of activity because of a strenuous physical
therapy regimen but denied any subjective fevers or chills. Her
white blood cell count at the time of presentation in the emergency
department was 12.1 103/mL, erythrocyte sedimentation rate and
C-reactive protein level were 8 mm/h and 7.36 mg/L, respectively,
and ﬁbrinogen level was 60 mg/dL. The patient's knee was aspi-
rated given the concern for infection. Synovial analysis revealed a
milky, white ﬂuid with a nucleated cell count of 3778/CMM and a
neutrophil count of 100%. Gram stain showed moderate gram-
positive cocci and the ﬁnal culture grew methicillin-sensitive
staphylococcus aureus.
A decision was made to return to the operating room for irri-
gation and debridement, along with polyethylene exchange and
implant retention. Gross purulence alongwith old hematoma in the
knee joint was noted at the time of the surgery. Intraoperative
cultures were also consistent with methicillin-sensitive staphylo-
coccus aureus. The patient was discharged on a 6-week course of
cefazolin and rifampin as recommended by the Infectious Disease
service. Close follow-up was arranged with orthopaedic surgery,
infectious disease, and hematology. Her ﬁbrinogen levels after the
second operationwere checkedweekly with a goal of maintaining a
level >100 mg/dL for a minimum of 4 weeks.
On most recent 1-year follow-up from her index procedure, she
reported good overall knee function with minimal discomfort. Shehad returned to performing most of her activities of daily activities
with minimal limitations. Her documented range of motion was 0-
124. There were no clinical signs of residual infection, and her C-
reactive protein value was 6.2. Imaging at this time demonstrated
satisfactory component alignment (Fig. 3).
Discussion
This is the ﬁrst reported case of a patient diagnosed with
hypoﬁbrinogenemia undergoing an elective TKA. Patients with
hypoﬁbrinogenemia are typically asymptomatic at baseline but
remain at risk for hemodynamic complications after trauma or
surgery [10,11]. Previous case reports have demonstrated that pa-
tients with aﬁbrinogenemia may experience signiﬁcant post-
operative bleeding [11]. Postoperative bleeding is a known
contributor to the development of deep infection, which has been
consistently demonstrated in the hemophiliac patient population
[12,13]. Because of this potential risk, current hematology practice
includes prophylactically treating the patient in advance of elective
procedures to raise serum ﬁbrinogen levels >100 mg/dL in the
immediate perioperative period. It remains unclear how long this
level should be maintained, or how frequently ﬁbrinogen levels
should be checked, particularly when considering elective
arthroplasty.
Epidemiology
Congenital ﬁbrinogen disorders are among the rarest bleeding
disorders [1,3-5,7,10,14,15]. Researchers estimate an incidence of 1
in 1 million within the general population [4]. The prevalence of
this disorder appears to be similar in men and women. Patients
with homozygous mutations exhibited complete ﬁbrinogen deﬁ-
ciency, whereas those with a heterozygous mutation experienced
abnormal bleeding during pregnancy and after trauma [3].
Genetics
Fibrinogen is a glycoprotein that is composed of two identical
polypeptide chains (Fig. 4). Each one of these chains is a compila-
tion of three genetically unique polypeptides (alpha, beta, and
gamma), which are all located on chromosome 4 and are suscep-
tible to mutations, resulting in clinical deﬁciency [15,16].
Congenital disorders of ﬁbrinogen may result from production
of an abnormal protein (dysﬁbrinogenemia), a reduction (hypoﬁ-
brinogenemia) or a complete lack of production (aﬁbrinogenemia)
[5]. Over 90% of mutations responsible for dysﬁbrinogenemia are
missense mutations at a functionally or structurally active site of
the polypeptide [14]. Patients with hypoﬁbrinogenemia or aﬁ-
brinogenemia usually suffer from a truncating mutation in the
alpha chain that prevents a functionally signiﬁcant portion of the
protein from being synthesized [15]. The patient reported in this
study was diagnosed with hypoﬁbrinogenemia.
Pathophysiology
Fibrinogen is a key contributor to hemostasis, assisting with clot
formation, platelet aggregation, and ﬁbrinolysis [4,5]. It is the most
abundant clotting factor in the human circulation, with normal
concentrations typically ranging from 2.0 to 4.5 g/L [10].
As the clotting cascade progresses in the normal individual,
ﬁbrinogen is cleaved by thrombin into the active monomer ﬁbrin
(Fig. 5). After cleavage, neighboring ﬁbrin monomers polymerize
via noncovalent and covalent bonds at the D-domain to form a
ﬁbrin clot [17,18]. It is cleavage of this ﬁbrin-ﬁbrin bond at the
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evaluate the presence of a clot in the circulatory system.
Diagnosis and laboratory analysis
As with other inherited coagulation disorders, patients may
report a history of excessive bleeding when challenged such as
during dental extraction or pregnancy. Impaired healing may also
be a manifestation. Patients with complete deﬁciency, aﬁ-
brinogenemia, may even experience thrombotic events. Of note, in
mild cases of hypoﬁbrinogenemia, symptoms often go unnoticed.
Such reports or a known family history should prompt a hema-
tology workup initially with a basic coagulation proﬁle including
PT, INR, and aPTT. Further analysis of these valuesmay guide further
testing. For example, a normal aPTT and prolonged PT/INR may be
more suggestive of FVII deﬁciency, whereas both tests prolonged
are nonspeciﬁc for many other deﬁciencies.
In congenital ﬁbrinogen deﬁciency, PT/INR and aPTT are all
elevated to a variable amount depending on the severity of ﬁbrin-
ogen deﬁciency. The intrinsic and extrinsic pathways both involve
ﬁbrinogen in their clotting cascade, and hence, both PTand aPTTare
affected. In our patient, both INR and PT were slightly elevated with
a normal aPTT. When suspecting a ﬁbrinogen deﬁciency, ﬁbrinogen
can speciﬁcally be measured by functional (Clauss method) and/or
antigenic assays (enzyme-linked immunosorbent assay). This is
typically sought out after a negative workup for less rare disorders
such as hemophilia A and B (factor VIII and IX deﬁciency) [2,3].
Treatment and recommendations
Current options for ﬁbrinogen repletion in deﬁcient patients
include FFP, cryo, and FC [1-3,6,7,10,19]. The United Kingdom Hae-
mophilia Centre Doctors' Organisation recommends that ﬁbrinogen
levels are maintained >100 mg/dL for hemostasis and >50 mg/dL
until wound healing is complete in patients with aﬁbrinogenemia
[7]. In a survey conducted by Peyvandi et al. [11], the authors noted
that patients experiencing minor bleeding episodes were treated
with targeted ﬁbrinogen levels of >100 mg/dL and those with more
severe episodes such as central nervous system bleeding were
treated with targeted levels of >150 mg/dL. The authors of another
study discovered that most cases of inadequate hemostatic control
or early bleedingwere associatedwith ﬁbrinogen levels<75mg/dL.
They also noted that in surgical cases with satisfactory hemostasis,
a plasma ﬁbrinogen level ranging from 100 mg/dL to 200 mg/dL
was achieved at the time of surgery [2].
In addition to a target ﬁbrinogen level, the recommended
duration of perioperative treatment also lacks formal guidelines. In
a case report by Reidy et al. [8], a patient with aﬁbrinogenemia was
successfully treated with a total elbow arthroplasty in which
ﬁbrinogen levels were maintained >50 mg/dL in the perioperative
and early postoperative periods. The patient was closely monitored
with weekly ﬁbrinogen levels and administration of FC for another
18weeks postoperatively until back on his preoperative regimen. In
another case report, a patient with congenital hypoﬁbrinogenemia
and a preoperative ﬁbrinogen level of 110 mg/dL undergoing aortic
valve replacement/coronary artery bypass grafting was treated
successfully for a total of 6 days while inpatient maintaining
ﬁbrinogen levels no lower than 280 mg/dL [20]. As demonstrated,
patients can successfully be treated with a wide range of target
ﬁbrinogen levels and duration of treatment. This decision may be
inﬂuenced by the severity of the deﬁciency and the invasiveness of
the surgical procedure.
Given the lack of formal guidelines for appropriate management
of hypoﬁbrinogenemia after total joint arthroplasty, we chose to
maintain ﬁbrinogen levels more than 100 mg/dL for our patient inthe immediate perioperative period, which provided satisfactory
hemostatic control initially. We also elected to rest her knee with
compression and bracing for the ﬁrst postoperative week to further
reduce the risk of hemarthrosis.
Despite data supporting the use of replacement products in the
perioperative period, the particular selection of a replacement
product remains controversial. Transfusion-associated complica-
tions may limit the use of FFP and cryo [2,21]. FFP is associated with
acute lung injury and volume overload. Both cryo and FFP consist of
many other plasma proteins in addition to ﬁbrinogen including
ﬁbronectin, von Willebrand factor, factor VIII, factor XIII, and other
potential anaphylatoxins putting patients at risk for allergic re-
actions [2]. Additionally, there is concern that the use of cryo poses
a higher risk of viral transmission given the lack of virus inactiva-
tion during its preparation. Recently, the use of FC has gained more
popularity.
Studies have shown FC to be equally effective in the treatment of
aﬁbrinogenemia when compared to cryo [2,19,21,22]. Distinct ad-
vantages of FC may include a better safety proﬁle given the lack of
aforementioned proteins and viral inactivation, as well as more
accurate dosing and rapid administration. However, availability and
increased costs have limited its use [21]. In our case, cryo was
selected as an effective treatment choice.Septic complications
Postoperative hemarthrosis is a key contributor to the devel-
opment of deep joint infection. This has been well documented in
the hemophiliac population undergoing TKA, with an overall
infection rate of 7.9% [13]. Impaired hemostasis may impact the
development of infection directly and indirectly [23]. A variety of
postsurgical complications have been documented for patients
with bleeding disorders including poor wound healing, increased
transfusion requirements, and higher pain scores [23]. A recent
article by Wong et al. [13] reported that hemophilia patients on a
high clotting-factor replacement regime for the ﬁrst two post-
operative weeks had a substantially lower rate of prosthetic joint
infections than patients who were maintained on the standard
replacement guidelines from the World Federation of Hemophilia.
Levels were measured and maintained at the time of surgery, 72
hours, 1 week, and 2 weeks postoperatively (2.15% vs 9.22%, P ¼
.005).
In our patient, owing to the lack of close hematology follow-up,
we failed to ensure that ﬁbrinogen levels were appropriately
maintained for postoperative healing beyond the ﬁrst 72 hours
after the TKA. The patient's ﬁbrinogen levels likely descended
below the target level after the inpatient stay. When considered in
combination with her increased activity levels during therapy for
her TKA, the lower ﬁbrinogen levels may have contributed to the
development of a postoperative hemarthrosis, thereby putting her
at a theoretically higher risk for prosthetic joint infection.Summary
We report a case in which a patient diagnosed with hypoﬁ-
brinogenemia was successfully treated with a TKA. Despite efforts
tomanage this disorder perioperatively and limit the possibility of a
hemarthrosis, the patient's postoperative course was complicated
by an acute prosthetic joint infection. Patients with hypoﬁ-
brinogenemia may often be asymptomatic without signiﬁcant
bleeding diathesis but are at risk of hemodynamic complications
and postoperative infection; these risks are likely magniﬁed when
considering total joint arthroplasty.
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Although no guidelines currently exist for the surgical care of
patients with these rare disorders, successful perioperative man-
agement of these patients may be possible by achieving and
maintaining a target goal for the ﬁbrinogen level >100mg/dL at the
time of surgery. This goal is based on clinical reasoning and prior
literature and is subject to modiﬁcation secondary to the severity of
the deﬁciency and procedure invasiveness. Based on our experi-
ence, we would recommend routine assessment of ﬁbrinogen
levels postoperatively with the use of FFP, cryo, or FC transfusion to
maintain the patient in the target range to decrease the risk of
hemarthrosis or acute prosthetic joint infection. Preoperative
consultation and perioperative comanagement with a hematologist
is also an essential element of care for patients with these rare
disorders. Further work is required including randomized
controlled trials to determine the optimal postoperative testing and
treatment regimen in orthopaedic patients.KEY POINTS
 Important to inquire about a history or a family history of
bleeding complications secondary to surgery.
 Any coagulation proﬁle lab abnormalities should prompt a
hematology consult pre-operatively.
 Extremely close follow-up is required of these patients post-
operatively secondary to higher risk of complications.References
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